Novartis NewsStarkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen arcticnovartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2024-01-31 08:02:352024-01-31 08:02:35Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
Novartis NewsNovartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III arcticnovartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2024-01-31 08:02:352024-01-31 08:02:35Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
Novartis NewsNovartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts arcticnovartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2024-01-31 08:02:332024-01-31 08:02:33Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Novartis NewsIn Colombia, a researcher works against a devastating disease
In Colombia, a researcher works against a devastating disease tavasat1
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00tavasat1http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngtavasat12024-01-25 15:39:302024-01-25 15:39:30In Colombia, a researcher works against a devastating disease
Novartis NewsGoing upstream to improve heart health in Philadelphia
Going upstream to improve heart health in Philadelphia mihai_novartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00mihai_novartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngmihai_novartis2024-01-25 14:39:492024-01-25 14:39:49Going upstream to improve heart health in Philadelphia
Novartis NewsA cancer patient gets a new lease on life
A cancer patient gets a new lease on life tavasat1
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00tavasat1http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngtavasat12024-01-25 14:19:592024-01-25 14:19:59A cancer patient gets a new lease on life
Novartis NewsA cancer patient gets a new lease on life
A cancer patient gets a new lease on life tavasat1
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00tavasat1http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngtavasat12024-01-25 14:19:592024-01-25 14:19:59A cancer patient gets a new lease on life
Novartis NewsEmpowering the next generation of healthcare leaders
Empowering the next generation of healthcare leaders attila_novartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00attila_novartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngattila_novartis2024-01-25 14:08:042024-01-25 14:08:04Empowering the next generation of healthcare leaders
Novartis NewsEmpowering the next generation of healthcare leaders
Empowering the next generation of healthcare leaders attila_novartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00attila_novartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngattila_novartis2024-01-25 14:08:042024-01-25 14:08:04Empowering the next generation of healthcare leaders
Novartis NewsGiving voice to people with a misunderstood disease
Giving voice to people with a misunderstood disease mihai_novartis
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00mihai_novartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngmihai_novartis2024-01-25 12:16:482024-01-25 12:16:48Giving voice to people with a misunderstood disease
